Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like FDA Expands Bristol-Myers Squibb’s Opdivo Dosing Schedule March 5, 2018 Takeda Showcases Broadened Oncology Portfolio Through Data Presentations At Upcoming Medical Meetings May 23, 2017 GTX Corp To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City September 21, 2017
Takeda Showcases Broadened Oncology Portfolio Through Data Presentations At Upcoming Medical Meetings May 23, 2017
GTX Corp To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City September 21, 2017